Clinical trial · Interventional
Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer
A Phase II Study of Neoadjuvant Chemotherapy With Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer
NCT01471470CI-TRIAL-00042644completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether docetaxel, capecitabine, cisplatin, and bevacizumab are effective in the treatment of unresectable advanced gastric cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Docetaxel, Capecitabine, Cisplatin, Bevacizumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- neoadjuvant
- interventionNames
- Drug: Docetaxel, Capecitabine, Cisplatin, Bevacizumab
Primary outcomes (1)
- measure
- R0 resection rate
- timeFrame
- Up to 4 weeks after surgery
- description
- R0 resection means complete resection of tumor.
Secondary outcomes (4)
- measure
- Overall survival
- timeFrame
- Up to 3 years
- description
- Overall survival will be measured from the start of study treatment to documented death of any cause.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically documented adenocarcinoma of the stomach or gastroesophageal junction. * Invasion to adjacent organ (T4) proven by endoscopic ultrasonography (EUS) or presence of paraaortic lymph node metastasis by CT and PET(short-axis diameter \> 1 cm showing hot uptake in PET scan). * Age 18-70 years old * ECOG performance status 0-2 * Adequate hepatic function(serum bilirubin \<1.5mg/dl, AST (SGOT) and ALT (SGPT) \< 2.5 x UNL, alkaline phosphatase \< 5 x UNL) * Adequate renal function(serum creatinine \<1.5mg/dl) * Adequate bone marrow function (WBC ≥4000 cell/㎕ with ANC ≥1500 cell/㎕, platelet count ≥100,000 cell/㎕) * HER2 negative (HER2 immunohistochemistry 0 or 1+, immunohistochemistry 2+ but FISH negative) * Informed consent Exclusion Criteria: * Other histologic type than adenocarcinoma * Metastasis in other sites than paraaortic lymph nodes, like in liver or peritoneum. * Presence or history of other cancers * History of prior chemotherapy, antiangiogenic agents, or radiation. * Patients with definite ascites in abdomen CT scan * Presence of not adequately controlled CNS metastasis * Bowel obstruction * Evidence of gastrointestinal bleeding * Other serious illness or medical conditions including hypertension uncontrolled by medication. * Pregnant or lactating women
References
Publications (0)
Data not yet available
No reference posted for this study.